Biopharmaceutical company AbbVie has announced the start of the 2017 Thriving Student Scholarship contest.
Each of the 3 winners, all of whom will be cystic fibrosis (CF) patients, will be awarded $25,000 in scholarship funds. Bloggers with a focus on the condition will be selected by the company to cover the competition and evaluate the students’ creative presentations, and one non-winner will be presented with the Blogger’s Choice Award. This recipient will be recognized for his or her creativity as a way to honor the scholarship program’s 25th
CF is a genetic condition that is often life-threatening and results in damage to a patient’s lungs and digestive systems. It is caused by a faulty or missing cystic fibrosis transmembrane conductance regulator (CFTR) proteins, and frequent lung infections, heavy coughing and difficulty breathing are among the most common conditions. Current treatment options for the disease include management of these symptoms.
Patients are often misdiagnosed with asthma or some other pulmonary ailment, and CF currently affects an estimated 30,000 people in the United States.
"25 years ago, students with CF faced immeasurable challenges fulfilling their goals of achieving higher education," said Jim Hynd, vice president, U.S. Specialty Products, AbbVie in a press release
. "In honor of the 25th anniversary of AbbVie's CF Scholarship Program, AbbVie is proud to reflect on the accomplishments of this community and the advancements in modern medicine that have made it possible for students with CF to achieve their dreams, both in and out of the classroom."
The contest will include 40 participants, each of whom are either undergraduate or graduate students living with CF. All participants have already received $3,000 to use during the 2017-2018 academic year, and now can earn the title of Thriving Undergraduate or Graduate Student, or Blogger's Choice Award recipient, as well as an additional $22,000 in scholarship funding, making for the $25,000 total.
AbbVie does not require scholarship applicants to have taken, currently take, or intend to take any medicine or product marketed by AbbVie, and the biopharmaceutical company insists that it is not a consideration in the selection criteria.
More information about the AbbVie CF Scholarship criteria and application can be found at http://www.abbviecfscholarship.com/
For more patient-focused stories from the rare disease community, follow Rare Disease Report